EA201100730A1 - Комплекс включения пиноцембрина с циклодекстрином, способ его получения и применения - Google Patents

Комплекс включения пиноцембрина с циклодекстрином, способ его получения и применения

Info

Publication number
EA201100730A1
EA201100730A1 EA201100730A EA201100730A EA201100730A1 EA 201100730 A1 EA201100730 A1 EA 201100730A1 EA 201100730 A EA201100730 A EA 201100730A EA 201100730 A EA201100730 A EA 201100730A EA 201100730 A1 EA201100730 A1 EA 201100730A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pinocembrin
cyclodextrin
preparation
application
complex inclusion
Prior art date
Application number
EA201100730A
Other languages
English (en)
Other versions
EA020784B1 (ru
Inventor
Сун У
Гуаньхуа Ду
Янь Ци
Мей Гао
Циньгунь Ян
Хунмей Гуан
Вей Ли
Юэхуа Ван
Юаньфен Тун
Original Assignee
СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКЛ ТЕКНОЛОДЖИ (ШИЦЯЧЖУАН) КО., ЛТД.
Инститьют Ов Мэтириэ Медикэ, Чайниз Экэдэми Ов Медикл Сайэнсиз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКЛ ТЕКНОЛОДЖИ (ШИЦЯЧЖУАН) КО., ЛТД., Инститьют Ов Мэтириэ Медикэ, Чайниз Экэдэми Ов Медикл Сайэнсиз filed Critical СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКЛ ТЕКНОЛОДЖИ (ШИЦЯЧЖУАН) КО., ЛТД.
Publication of EA201100730A1 publication Critical patent/EA201100730A1/ru
Publication of EA020784B1 publication Critical patent/EA020784B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Предусмотрены комплексы включения пиноцембрина с циклодекстрином или его производными и их получение. Комплексы включения могут быть применены для получения лекарств.
EA201100730A 2008-11-11 2008-11-11 Комплекс включения пиноцембрина с циклодекстрином, способ его получения и применения EA020784B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2008/073011 WO2010054507A1 (zh) 2008-11-11 2008-11-11 松属素环糊精或环糊精衍生物包合物

Publications (2)

Publication Number Publication Date
EA201100730A1 true EA201100730A1 (ru) 2011-10-31
EA020784B1 EA020784B1 (ru) 2015-01-30

Family

ID=42169585

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100730A EA020784B1 (ru) 2008-11-11 2008-11-11 Комплекс включения пиноцембрина с циклодекстрином, способ его получения и применения

Country Status (17)

Country Link
US (1) US9949946B2 (ru)
EP (1) EP2359861B1 (ru)
JP (1) JP5413998B2 (ru)
KR (1) KR101563308B1 (ru)
AP (1) AP2011005707A0 (ru)
AU (1) AU2008364165B2 (ru)
BR (1) BRPI0823254A2 (ru)
CA (1) CA2743006C (ru)
CU (1) CU24034B1 (ru)
EA (1) EA020784B1 (ru)
ES (1) ES2438294T3 (ru)
HK (1) HK1155094A1 (ru)
IL (2) IL212819A (ru)
MX (1) MX2011004991A (ru)
UA (1) UA99979C2 (ru)
WO (1) WO2010054507A1 (ru)
ZA (1) ZA201103244B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022275B1 (ru) * 2008-12-11 2015-12-30 СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. Применение рацематов пиноцембрина для получения лекарственных средств для лечения инсульта
GR1007520B (el) * 2010-12-02 2012-02-02 Apivita - Καλλυντικα - Διαιτητικα - Φαρμακα Ανωνυμη Εμπορικη Και Βιοτεχνικη Εταιρεια, Ταυτοχρονη εκχυλιση και σχηματισμος συμπλοκων εγκλεισμου των δραστικων συστατικων της προπολης με υδροξυπροπυλο-β-κυκλοδεξτρινη
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
GB2584009B (en) 2017-08-28 2022-03-23 Revagenix Inc Aminoglycosides and uses thereof
US11673907B2 (en) 2018-04-03 2023-06-13 Revagenix, Inc. Modular synthesis of aminoglycosides
WO2020154447A1 (en) 2019-01-22 2020-07-30 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
KR102356618B1 (ko) * 2021-11-17 2022-02-08 명지대학교 산학협력단 신규 포접복합체 및 이의 용도
WO2023166488A1 (en) 2022-03-04 2023-09-07 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
JP3269737B2 (ja) * 1994-08-31 2002-04-02 宇野醤油株式会社 食品保存料、およびその製造方法
JP2782335B2 (ja) * 1996-03-04 1998-07-30 株式会社武田薬化学研究所 プロポリスの水分散液
CN1424112A (zh) * 2002-12-17 2003-06-18 上海医药工业研究院 难溶性药物的水溶性包合物及其制备方法
CN1285334C (zh) 2004-05-12 2006-11-22 中国医学科学院药物研究所 生松素在制备防治神经细胞损伤相关疾病药物中的应用
JP2008507522A (ja) * 2004-07-23 2008-03-13 ザ プロクター アンド ギャンブル カンパニー フラボノイドとビタミンｂ３を含有するスキンケア組成物
CN1739537A (zh) 2004-08-26 2006-03-01 张红军 灯盏花素环糊精包合物及其制剂
KR100601395B1 (ko) * 2004-11-04 2006-07-18 한국식품연구원 수용성 프로폴리스 추출물 및 분말의 제조 방법
CN1311815C (zh) * 2005-05-08 2007-04-25 浙江大学 亚微米蜂胶微胶囊的制备方法
CN1879656B (zh) * 2006-04-27 2010-04-21 魏春华 固体水溶性蜂胶组合物及其制备方法

Also Published As

Publication number Publication date
EA020784B1 (ru) 2015-01-30
UA99979C2 (ru) 2012-10-25
MX2011004991A (es) 2011-07-29
KR20110098906A (ko) 2011-09-02
ZA201103244B (en) 2011-12-28
IL212819A0 (en) 2011-07-31
AP2011005707A0 (en) 2011-06-30
CU24034B1 (es) 2014-10-02
EP2359861A1 (en) 2011-08-24
ES2438294T3 (es) 2014-01-16
HK1155094A1 (en) 2012-08-03
EP2359861B1 (en) 2013-09-11
CU20110103A7 (es) 2012-01-31
CA2743006C (en) 2016-02-09
AU2008364165A1 (en) 2010-05-20
BRPI0823254A2 (pt) 2015-06-23
AU2008364165B2 (en) 2015-01-29
JP2012508191A (ja) 2012-04-05
US20110218173A1 (en) 2011-09-08
WO2010054507A1 (zh) 2010-05-20
KR101563308B1 (ko) 2015-10-26
US9949946B2 (en) 2018-04-24
JP5413998B2 (ja) 2014-02-12
IL212819A (en) 2015-07-30
EP2359861A4 (en) 2012-05-02
CA2743006A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
EA201100730A1 (ru) Комплекс включения пиноцембрина с циклодекстрином, способ его получения и применения
CY1123208T1 (el) Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
BR112015030514A2 (pt) Composições e métodos para conjugação de anticorpos ativáveis
EA201071320A1 (ru) Активаторы глюкокиназы
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
MA32363B1 (fr) Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine.
EA201270254A1 (ru) Производные 5-фторпиримидинона
EA201491009A1 (ru) Гель лизата тромбоцитов
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201791850A1 (ru) Борсодержащие малые молекулы
MX2016008448A (es) Conjugados de var2csa-farmaco.
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
BR112012023910A2 (pt) preparações cosméticas ou dermatológicas com um teor de um ou mais derivados de tiazol
EA201590617A1 (ru) Композиции алкилированного циклодекстрина и способы их получения и применения
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201201623A1 (ru) Лечение диабета 2 типа
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU